India's anti-obesity drug market has grown more than fourfold in the last five years
India's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven ...
India’s anti-obesity drug market quadruples in five years on lifestyle disease surge
India's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025.
LLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now?
Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Lilly markets its dual GIP and GLP-1 receptor agonist, ...
Health and Me on MSN6h
Novo Nordisk's Diabetes Drug Could Be Beneficial For Heart, Study Shows
Rybelsus reduced the risk of cardiovascular-related death, heart attack, and stroke by 14% compared to a placebo over an ...
Trump Administration Reverses Biden's Plan For Medicare Coverage Of Obesity Drugs Like Ozempic And Zepbound
Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.
Beyond weight loss: Can Ozempic sharpen your brain, cut dementia risk?
Weight loss drugs like Ozempic gained popularity for managing obesity, diabetes, and related chronic conditions, a new study ...
ThePrint on MSN5h
Big buzz over Mounjaro launch but here’s why India’s anti-obesity drug market may only take off next yr
India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...
Smoking out quacks on World Health Day
Quack cardiac surgeries, World Health Day policies, Trump's healthcare decisions, anti-obesity drug coverage, and more health ...